Skip to content

DAN-WAR-D - Danish Warfarin-Dialysis Study: Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis -A nationwide parallel-group open randomized clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502500-75-00
Acronym
02022018
Enrollment
718
Registered
2023-01-11
Start date
2024-01-30
Completion date
Unknown
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation, End-stage renal disease

Brief summary

any transient ischemic attack, ischemic or unspecified stroke or death due to a transient ischemic attack, ischemic or unspecified stroke will be compared between patients allocated warfarin and no treatment.

Detailed description

major bleeding defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients, i.e. major intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, intramuscular with compartment syndrome, or gastrointestinal bleeding.

Interventions

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
any transient ischemic attack, ischemic or unspecified stroke or death due to a transient ischemic attack, ischemic or unspecified stroke will be compared between patients allocated warfarin and no treatment.

Secondary

MeasureTime frame
major bleeding defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients, i.e. major intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, intramuscular with compartment syndrome, or gastrointestinal bleeding.

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 7, 2026